Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Published on September 29, 2012 at 2:27 AM · No Comments
Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.  The analysis was performed to facilitate selection of a dosing regimen to be further examined the ITCA 650 global phase 3 clinical program.      

The abstract submission entitled, "Optimising phase 3 dose selection with ITCA 650: correlation between baseline HbA1c and reduction of HbA1c after 24 weeks of treatment," by R.R. Henry, J. Rosenstock, M. Baron, K. Luskey, and T. Alessi, was accepted for an oral presentation.  The presenting author will be Robert R. Henry, MD, Chief of the Section of Diabetes, Endocrinology and Metabolism at the University of California, San Diego. The presentation (number 109) will take place in the Langerhans Hall, on Wednesday October 3, 2012, in Session OP 19 (Novel Therapies) from 2:30 PM - 4:00 PM Session.

Source:

Intarcia Therapeutics, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Intake of arsenic linked to cardiovascular disease, diabetes